Toxicities will be graded using the NCI CTCAE Version 4.03. Efficacy: ORR and PFS will be assessed by CT of target and non -target lesions every 8 weeks during the induction phase and every 12 weeks during the maintenance phase and will be evaluated in accordance with RECIST Version 1.1 and irRC. OS, DOR, and DCR will also be assessed. An assessment of QoL will be conducted via PROs using the Functional Assessment of Cancer Therapy- Breast Cancer (FACT -B) instrument on study day 1, every 6 weeks thereafter (day 1 of weeks 7, 13, 19, etc ) prior to treatment , during induction phase, every 12 weeks during maintenance, and at the end-of- treatment (EOT) visit. Exploratory Analysis: Tumor Molecular Profiling: Genomic sequencing of tumor cells from tissue relative to non -tumor cells from whole blood will be conducted to identify tumor- specific genomic variances that may contribute to disease progression and/or response to treatment. RNA sequencing will be conducted to provide expression data and give relevance to DNA mutations. Quantitative proteomics analysis will be conducted to determine the absolute amounts of specific proteins, to confirm expression of genes that are correlative of disease progression and/or response, and to determine the cutoff values for response. Immunologic Analysis: Immune responses to the NANT TNBC vaccine regimen will be evaluated by standard immune assays. Correlations between therapy -induced immune changes and subject outcomes will be assessed. ctDNA/ctRNA Analysis : ctDNA and ctRNA will be extracted from plasma obtained from whole blood. Expression levels of specific tumor - and immune- related analytes will be assessed by quantitative real -time polymerase chain reaction (qPCR) and possibly other methods (eg, DNA/RNA sequencing) and analyzed for correlations with subject outcomes. Statistical Methods: This phase 1b/2 stud y will examine the overall safety profile and preliminary efficacy of metronomic combination therapy in subjects with TNBC whose tumors have progressed on or after SoC treatment. Safety results will be presented separately for the induction and maintenance phases of treatment as well as overall for the entire treatment regimen.